Myasthenia Gravis Pseudoparalytica

Myasthenia gravis pseudoparalytica is a severe form of myasthenia gravis, which is characterized by severe muscle weakness. The name "pseudoparalytica" comes from the Greek words "pseudo" (false) and "paralysis" (paralysis).

This disease is caused by a disruption in the transmission of nerve impulses from nerves to muscles due to a decrease in the number of acetylcholine receptors on the surface of muscle fibers. As a result, fatigue and weakness of skeletal muscles develop.

Myasthenia gravis pseudoparalytica affects the muscles of the limbs, trunk, face, pharynx and larynx. Muscle weakness increases with physical activity and decreases after rest. However, over time, the muscles weaken even at rest. This leads to severe disability.

Anticholinesterase drugs, glucocorticoids and immunomodulators are used for treatment. Plasmapheresis may also be required. In case of severe breathing disorders, artificial ventilation is necessary. The prognosis of the disease is serious, but with adequate treatment, a significant improvement in the patient's condition is possible.

Myasthenia gravis pseudoparalytica is a severe form of myasthenia gravis characterized by severe muscle weakness resembling paralysis.

In this form of the disease, almost all skeletal muscles are affected, including the muscles of the pharynx, larynx, and respiratory muscles. Severe speech, swallowing and breathing problems may develop.

Distinctive features of myasthenia gravis pseudoparalytica are rapid muscle fatigue and their recovery after rest. However, over time, muscle weakness increases and the muscles almost completely lose their strength.

Treatment includes immunosuppressive therapy, plasmapheresis, and administration of cholinesterase inhibitors. The prognosis with adequate treatment can be relatively favorable.